Cargando…

Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components

We present two cases of pulmonary pleomorphic carcinoma (PPC) treated with Nivolumab. A 57‐year‐old man presented with a 3.5‐cm mass in the left lower lobe. Left lower lobectomy and lymph node dissection were performed. Histological diagnosis was stage IIIA (pT2bN2M0) PPC. The tumour relapsed two mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ota, Takahiro, Niho, Seiji, Kirita, Keisuke, Ishii, Genichiro, Tsuboi, Masahiro, Goto, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702315/
https://www.ncbi.nlm.nih.gov/pubmed/31452896
http://dx.doi.org/10.1002/rcr2.477
_version_ 1783445203186614272
author Ota, Takahiro
Niho, Seiji
Kirita, Keisuke
Ishii, Genichiro
Tsuboi, Masahiro
Goto, Koichi
author_facet Ota, Takahiro
Niho, Seiji
Kirita, Keisuke
Ishii, Genichiro
Tsuboi, Masahiro
Goto, Koichi
author_sort Ota, Takahiro
collection PubMed
description We present two cases of pulmonary pleomorphic carcinoma (PPC) treated with Nivolumab. A 57‐year‐old man presented with a 3.5‐cm mass in the left lower lobe. Left lower lobectomy and lymph node dissection were performed. Histological diagnosis was stage IIIA (pT2bN2M0) PPC. The tumour relapsed two months later and he was treated with carboplatin and paclitaxel, but his condition became progressive and nonresponsive after one cycle. We used nivolumab as second line. Repeat chest X‐ray showed impressive reduction of relapse lesions seven days after the start of nivolumab therapy. Our second case is a 50‐year‐old man who presented with a 3.7‐cm mass in the right lower lobe and submucosal tumour in the colon. Endobronchial ultrasound‐guided transbronchial needle aspiration biopsy (EBUS‐TBNA) and colon biopsy yield the diagnosis of PPC and metastatic colon cancer. He was treated with cisplatin plus pemetrexed. His disease proved resistant and we used nivolumab as second line. He showed partial response following four cycles.
format Online
Article
Text
id pubmed-6702315
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-67023152019-08-26 Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components Ota, Takahiro Niho, Seiji Kirita, Keisuke Ishii, Genichiro Tsuboi, Masahiro Goto, Koichi Respirol Case Rep Case Reports We present two cases of pulmonary pleomorphic carcinoma (PPC) treated with Nivolumab. A 57‐year‐old man presented with a 3.5‐cm mass in the left lower lobe. Left lower lobectomy and lymph node dissection were performed. Histological diagnosis was stage IIIA (pT2bN2M0) PPC. The tumour relapsed two months later and he was treated with carboplatin and paclitaxel, but his condition became progressive and nonresponsive after one cycle. We used nivolumab as second line. Repeat chest X‐ray showed impressive reduction of relapse lesions seven days after the start of nivolumab therapy. Our second case is a 50‐year‐old man who presented with a 3.7‐cm mass in the right lower lobe and submucosal tumour in the colon. Endobronchial ultrasound‐guided transbronchial needle aspiration biopsy (EBUS‐TBNA) and colon biopsy yield the diagnosis of PPC and metastatic colon cancer. He was treated with cisplatin plus pemetrexed. His disease proved resistant and we used nivolumab as second line. He showed partial response following four cycles. John Wiley & Sons, Ltd 2019-08-20 /pmc/articles/PMC6702315/ /pubmed/31452896 http://dx.doi.org/10.1002/rcr2.477 Text en © 2019 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Ota, Takahiro
Niho, Seiji
Kirita, Keisuke
Ishii, Genichiro
Tsuboi, Masahiro
Goto, Koichi
Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components
title Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components
title_full Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components
title_fullStr Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components
title_full_unstemmed Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components
title_short Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components
title_sort impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702315/
https://www.ncbi.nlm.nih.gov/pubmed/31452896
http://dx.doi.org/10.1002/rcr2.477
work_keys_str_mv AT otatakahiro impressiveresponsetonivolumabofnonsmallcelllungcancercontainingsarcomatoidcomponents
AT nihoseiji impressiveresponsetonivolumabofnonsmallcelllungcancercontainingsarcomatoidcomponents
AT kiritakeisuke impressiveresponsetonivolumabofnonsmallcelllungcancercontainingsarcomatoidcomponents
AT ishiigenichiro impressiveresponsetonivolumabofnonsmallcelllungcancercontainingsarcomatoidcomponents
AT tsuboimasahiro impressiveresponsetonivolumabofnonsmallcelllungcancercontainingsarcomatoidcomponents
AT gotokoichi impressiveresponsetonivolumabofnonsmallcelllungcancercontainingsarcomatoidcomponents